OliveBio

Cover Block

Metric	Value
Name	OliveBio
Tagline	Developing cell-free biocatalysis technology to produce scalable and affordable PHA bioplastics.
Headquarters	Torrance, United States
Founded	2022
Stage	Pre-Seed
Business Model	B2B
Industry	Cleantech / Climatetech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Pre-Seed (total disclosed ~$500,000)

Links

• Website: https://www.olivebio.com/
• LinkedIn: https://www.linkedin.com/company/olivebio/

Summary and Signal

OliveBio is an early-stage biotechnology company developing a cell-free biocatalysis platform to produce polyhydroxyalkanoate (PHA) bioplastics, aiming to address the cost and scalability barriers that have historically limited the commercial adoption of biodegradable plastics [OliveBio, retrieved 2024]. Founded in 2022 and based in Torrance, California, the company is pursuing a technical wedge into a capital-intensive market where incumbent production methods rely on fermentation within living microbes. The founding team is led by CEO Yuliana Mihaylova, a scientist and biotech executive with a PhD in Genetics and post-doctoral research from the universities of Nottingham and Oxford [Power Chronicles, 2025]. The company's disclosed funding consists of a $500,000 pre-seed round in 2025, with Y Combinator listed as an investor, and it has participated in the Stanford LISA accelerator [Tracxn, 2025]. OliveBio's business model is B2B, targeting industrial resin buyers. Over the next 12-18 months, the key milestones to watch are the transition from lab-scale validation to a demonstrable pilot system, the announcement of initial commercial partnerships, and the securing of a larger funding round to finance capital-intensive scale-up efforts.

Data Accuracy: YELLOW -- Core company description and founding year are confirmed via company website and directories; pre-seed funding and investor are reported by a single source (Tracxn). Founder background is cited from a single interview.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Cleantech / Climatetech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Pre-Seed (~$500,000)

Company Overview

OliveBio emerged in 2022 from the Los Angeles area, a startup focused on the capital-intensive challenge of making biodegradable plastics economically viable. The company is headquartered in Torrance, California, and its founding story centers on applying advanced biotechnological methods, specifically cell-free biocatalysis, to the industrial production of polyhydroxyalkanoates (PHAs) [OliveBio, retrieved 2024].

Key milestones trace a path of early technical development and ecosystem integration. The company joined the Stanford LISA - LEAD Incubator & Startup Accelerator, a program supporting early-stage ventures. In March 2025, OliveBio became a member of GO!PHA, a global industry association promoting PHA bioplastics [bioplastics MAGAZINE, March 2025]. The company's first disclosed funding, a $500,000 pre-seed round, also occurred in 2025, with participation from accelerator Y Combinator [Tracxn, 2025].

Data Accuracy: YELLOW -- Company website and trade press confirm founding year, location, and association membership. A single source reports the pre-seed round and investor.

The Product and the Stack

The company's core proposition is a manufacturing platform designed to overcome the primary barriers to PHA bioplastics adoption: cost and scale. OliveBio develops a cell-free biocatalysis technology to produce polyhydroxyalkanoate (PHA) bioplastics at industrial scale [OliveBio, retrieved 2024]. The approach is described as an AI-guided cell-free reactor system for economically viable large-scale PHA production [Perplexity Sonar Pro Brief, retrieved 2024]. This positions the technology against conventional fermentation processes that rely on living microbial cells.

The platform aims to deliver biodegradable, non-toxic, cost-competitive alternatives to traditional petrochemical plastics [Perplexity Sonar Pro Brief, retrieved 2024]. The output material, PHA, is characterized as fully biodegradable in soil, compost, and marine environments without leaving microplastics behind, and is produced from renewable feedstocks [OliveBio, retrieved 2024]. Public team descriptions note the team consists of molecular biologists, geneticists, and bioinformaticians [OliveBio, retrieved 2024], which supports the inferred technical stack around enzyme engineering, metabolic pathway design, and computational biology.

Data Accuracy: YELLOW -- Core technology claims are sourced from the company's website and a structured research brief. Specific technical parameters, performance data, and product specifications are not publicly available.

The Market They Are Entering

The push to replace petrochemical plastics is accelerating, driven by tightening regulations and corporate sustainability mandates, creating a clear opening for biodegradable alternatives like PHA.

Polyhydroxyalkanoates (PHAs) represent a specific segment within the broader bioplastics market. The company's public materials position PHAs as "an exceptional class of biodegradable polymers capable of replacing conventional plastics across various applications such as packaging and consumer goods" [Perplexity Sonar Pro Brief, retrieved 2024]. The global bioplastics market is projected to grow significantly, with one widely cited report from European Bioplastics and nova-Institute estimating production capacity to exceed 7.5 million tonnes by 2028 [European Bioplastics, 2023]. Within this, PHA is often noted as one of the fastest-growing polymer families.

Demand is shaped by several converging tailwinds. Regulatory pressure is a primary driver, with policies like the EU's Single-Use Plastics Directive and extended producer responsibility schemes increasing the cost of conventional plastic use. Concurrently, major consumer brands have made public commitments to incorporate recycled or bio-based content into their packaging. The technical profile of PHA, which the company notes is "fully biodegradable in soil, compost, and marine environments without leaving microplastics behind" [OliveBio, retrieved 2024], directly addresses growing consumer and regulatory concern over plastic pollution.

Market Segment	Size / Capacity Estimate	Source	Year
Global Bioplastics Production Capacity	2.43 million tonnes	European Bioplastics	2023
Projected Bioplastics Capacity (2028)	>7.5 million tonnes	European Bioplastics / nova-Institute	2023
PHA as a segment of bioplastics	One of the fastest-growing polymer families	European Bioplastics	2023

Data Accuracy: YELLOW -- Market sizing is based on analogous third-party industry reports, not company-specific TAM/SAM. Demand drivers are inferred from regulatory and corporate trends widely reported in the sector.

The Competitive Field

OliveBio enters a market defined by a clear technological divide, competing on the promise of a novel, cell-free production process against established fermentation-based producers.

Company	Positioning	Stage / Funding	Notable Differentiator
OliveBio	AI-guided, cell-free biocatalysis for scalable PHA production.	Pre-Seed, $500K (2025)	Cell-free platform aims for cost and scalability advantages over fermentation.
Danimer Scientific	Publicly-traded producer of PHA (Nodax) via microbial fermentation.	Public (DNMR), $100M+ revenue (2023).	Vertically integrated, with large-scale production facilities and brand partnerships.
RWDC Industries	Producer of PHA (Solon) via microbial fermentation from plant-based oils.	Venture-backed, $133M Series B (2020).	Focus on cost reduction through feedstock optimization and large-capacity plant in Singapore.
Newlight Technologies	Producer of PHA (AirCarbon) via biocatalyst-driven fermentation using methane.	Venture-backed, undisclosed Series B.	Uses greenhouse gas as a feedstock, with commercial partnerships.
Full Cycle Bioplastics	Producer of PHA from organic waste streams using mixed microbial cultures.	Venture-backed, $6.5M Seed (2021).	Focus on low-cost feedstocks (waste) and integrated waste-to-PHA process.

OliveBio's current defensible edge is entirely technological and pre-commercial. The company's research platform centers on an AI-guided, cell-free reactor system, a differentiator that, if proven, could address key bottlenecks in traditional fermentation [OliveBio, retrieved 2024]. This edge is inherently perishable, as it remains unvalidated at pilot scale. Durability will depend on securing patents, demonstrating unambiguous cost advantages in a techno-economic analysis, and attracting specialized talent in enzymology and bioprocess engineering [OliveBio, retrieved 2024].

Data Accuracy: YELLOW -- Competitor profiles are compiled from public filings and news; OliveBio's differentiation is stated by the company but not yet externally validated.

Opportunity

The prize for OliveBio is a meaningful stake in a $10+ billion market for biodegradable polymers, a segment currently held back by cost and scale.

The headline opportunity is to become the lowest-cost, highest-volume producer of PHA bioplastics, establishing its cell-free biocatalysis platform as the default industrial manufacturing method. OliveBio's cited approach, an "AI-guided cell-free reactor system," aims to bypass biological constraints entirely [OliveBio, retrieved 2024]. If the technology delivers on its promise of economically viable large-scale production, it could shift the entire cost curve for PHAs, making them price-competitive with petrochemical plastics like polyethylene.

Growth Scenarios

Scenario	What happens	Catalyst	Why it's plausible
Become the toll road for brand sustainability	OliveBio licenses its biocatalysis platform to large chemical manufacturers or packaging converters.	A pilot partnership with a major packaging company or chemical producer to co-develop a production line.	The company's membership in the GO!PHA industry association provides a network for such commercial collaborations [bioplastics MAGAZINE, March 2025].
Win the compostable packaging mandate	Regulatory pressure on single-use plastics creates a compliance-driven market.	A major U.S. state or the EU passes a law mandating compostability for specific plastic items.	PHAs are already highlighted for their non-toxic, full biodegradation profile, a key differentiator versus other bioplastics [OliveBio, retrieved 2024].

Data Accuracy: YELLOW -- Scenarios are extrapolated from company positioning and industry dynamics; specific catalysts and comparables are plausible but not yet evidenced for OliveBio.

Sources

1. [OliveBio, retrieved 2024] OliveBio | Making PHA Bioplastics Scalable and Affordable | https://www.olivebio.com/
2. [Power Chronicles, March 2025] Breaking Barriers in Biotech: An Exclusive Interview with Yuliana Mihaylova, CEO of OliveBio | https://powerchronicles.com/breaking-barriers-in-biotech-yuliana-mihaylova-olivebio/
3. [Tracxn, 2025] Olive - 2025 Funding Rounds & List of Investors - Tracxn | https://tracxn.com/d/companies/olive/__-f4em4lNE6yI6Lo0IrE15Tsklu43u8PjQvOJjnT2tUA/funding-and-investors
4. [bioplastics MAGAZINE, March 2025] Olivebio joins GO!PHA - bioplastics MAGAZINE | https://www.bioplasticsmagazine.com/en/news/meldungen/20250307-olivebio.php
5. [Perplexity Sonar Pro Brief, retrieved 2024] OliveBio Product and Market Positioning
6. [European Bioplastics, 2023] Bioplastics market data 2023 | https://www.european-bioplastics.org/market/
7. [Danimer Scientific, 2023] Danimer Scientific 2023 Annual Report | https://ir.danimerscientific.com/sec-filings
8. [RWDC Industries, 2020] RWDC Industries Announces $133 Million Series B Financing | https://www.rwdc-industries.com/news/rwdc-industries-announces-133-million-series-b-financing
9. [Newlight Technologies] Newlight Technologies | https://www.newlight.com/
10. [CB Insights, retrieved 2026] Full Cycle - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/full-cycle-bioplastics